CPA Applauds Brown, Baldwin Letter to USTR Tai Urging Support of U.S. PPE Production & to End Tariff Exclusions on Chinese PPE

WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded U.S. Senators Sherrod Brown (D-OH) and Tammy Baldwin (D-WI) for leading a letter to United States Trade Representative (USTR) Katherine Tai requesting that 301 penalty duties be assessed to all imported finished state personal protective equipment (PPE) and key raw material inputs, including single-use…

Details

CPA Urges USTR Tai Not to Expand 301 Tariff Exclusions on Chinese Imports

WASHINGTON — The Coalition for a Prosperous America (CPA) today urged U.S. Trade Representative Katherine Tai to not expand exclusions to Chinese imports subject to Section 301 tariffs. Currently, the Biden administration is reviewing 549 products currently subject to 301 tariffs imposed on Chinese imports. CPA strongly supports the current 301 tariffs on Chinese imports…

Details

Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman

CPA’s report, titled “Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman,” details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign…

Details

Tariff Incidence in the Real World: Why Consumers (Mostly) Didn’t Pay the Steel Tariffs

Summary points: The import price of steel fell in the period following the 2018 imposition of a 25% steel tariff, an indicator that steel tariffs were not passed entirely onto consumers. Steel tariffs did not lead to a proportional rise in consumer prices of steel-intensive goods, such as automobiles. In many instances, firms will internalize…

Details

New CPA Report Documents How Hatch-Waxman Act Loophole Led to Offshoring of Generics Production, Price Gouging, and Shortages

WASHINGTON — The Coalition for a Prosperous America (CPA) today released a new academic report that details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign companies in the U.S. The…

Details